WO2000006603A1 - Anticorps pour la detection de micro-organismes - Google Patents
Anticorps pour la detection de micro-organismes Download PDFInfo
- Publication number
- WO2000006603A1 WO2000006603A1 PCT/JP1999/004122 JP9904122W WO0006603A1 WO 2000006603 A1 WO2000006603 A1 WO 2000006603A1 JP 9904122 W JP9904122 W JP 9904122W WO 0006603 A1 WO0006603 A1 WO 0006603A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- protein
- microorganism
- ribosomal protein
- microorganisms
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 146
- 108050000743 Ribosomal protein L7/L12 Proteins 0.000 claims abstract description 125
- 102000008837 Ribosomal protein L7/L12 Human genes 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 83
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 24
- 108010000605 Ribosomal Proteins Proteins 0.000 claims abstract description 8
- 102000002278 Ribosomal Proteins Human genes 0.000 claims abstract description 8
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 63
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 50
- 241000606768 Haemophilus influenzae Species 0.000 claims description 49
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 30
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 126
- 241000894006 Bacteria Species 0.000 abstract description 21
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 229940126534 drug product Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 108
- 108090000623 proteins and genes Proteins 0.000 description 75
- 108020004414 DNA Proteins 0.000 description 66
- 239000006228 supernatant Substances 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 61
- 239000000203 mixture Substances 0.000 description 55
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 54
- 239000002953 phosphate buffered saline Substances 0.000 description 54
- 108091007433 antigens Proteins 0.000 description 44
- 102000036639 antigens Human genes 0.000 description 44
- 239000000427 antigen Substances 0.000 description 39
- 238000003752 polymerase chain reaction Methods 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 38
- 239000002609 medium Substances 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 36
- 210000004408 hybridoma Anatomy 0.000 description 33
- 238000005406 washing Methods 0.000 description 33
- 238000001514 detection method Methods 0.000 description 31
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 27
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 26
- 239000002244 precipitate Substances 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 23
- 239000013598 vector Substances 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 20
- 239000012980 RPMI-1640 medium Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 239000012679 serum free medium Substances 0.000 description 17
- 241000588653 Neisseria Species 0.000 description 14
- 102000003992 Peroxidases Human genes 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 239000012894 fetal calf serum Substances 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 108040007629 peroxidase activity proteins Proteins 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 108010037046 ribosomal protein L7-L12 Proteins 0.000 description 11
- 241000894007 species Species 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000011543 agarose gel Substances 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 230000007910 cell fusion Effects 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 8
- 239000013504 Triton X-100 Substances 0.000 description 8
- 229920004890 Triton X-100 Polymers 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 229910052710 silicon Inorganic materials 0.000 description 8
- 239000010703 silicon Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 241000606790 Haemophilus Species 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 229910052581 Si3N4 Inorganic materials 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 6
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 108010067770 Endopeptidase K Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000001978 anti-ribosomal effect Effects 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 230000001143 conditioned effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- SQAMFSBCDWMGTD-UHFFFAOYSA-O CC(O)=[S+]C(C)=O.ON(C(CC1)=O)C1=O Chemical compound CC(O)=[S+]C(C)=O.ON(C(CC1)=O)C1=O SQAMFSBCDWMGTD-UHFFFAOYSA-O 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000588650 Neisseria meningitidis Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000007330 chocolate agar Substances 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 102100025643 60S ribosomal protein L12 Human genes 0.000 description 3
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000009010 Bradford assay Methods 0.000 description 3
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101000575173 Homo sapiens 60S ribosomal protein L12 Proteins 0.000 description 3
- 101000659995 Homo sapiens Ribosomal L1 domain-containing protein 1 Proteins 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000003370 dye binding method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003317 immunochromatography Methods 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 241000588649 Neisseria lactamica Species 0.000 description 2
- 241000162058 Neisseria lactamica ATCC 23970 Species 0.000 description 2
- 241000588659 Neisseria mucosa Species 0.000 description 2
- 241000588645 Neisseria sicca Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108700011066 PreScission Protease Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical group CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241001385733 Aesculus indica Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000164287 Enterococcus faecalis ATCC 19433 Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 101710169972 Menin Proteins 0.000 description 1
- 102100030550 Menin Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100465000 Mus musculus Prag1 gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101000794863 Neisseria gonorrhoeae Anthranilate synthase component 1 Proteins 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000635 anti-gonococcal effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940063126 lidum Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006333 protein structural change Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000007160 ty medium Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56933—Mycoplasma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1253—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
Definitions
- the present invention relates to an antibody useful for detecting various microorganisms, particularly bacteria, a method for detecting microorganisms using the same, a reagent kit for detecting microorganisms, and a method for producing a specific antibody for detecting microorganisms.
- the present invention is effectively used in the pharmaceutical industry, particularly in the manufacture of a diagnostic drug for microbial infectious diseases centering on bacteria.
- Diagnosis of microbial infections is usually confirmed by detecting the causative organism at the site of infection, or by detecting antibodies to the causative organism in serum or body fluids. In particular, this diagnosis is important because the detection of the causative organism allows for rapid treatment of the patient.
- culture is performed by isolation and culture of the causative bacteria, and then the bacteria are identified based on their biochemical properties.
- Genetic diagnosis can be broadly divided into immunological methods for detecting the causative organism using the specific reaction of the antibody with the surface antigen marker of the causative organism, but the culture identification method and the genetic diagnostic method can provide detection results Diagnosis by immunoassay is widely used because it takes a long time to detect the causative bacteria in a short time and with high sensitivity, and leads to prompt and appropriate treatment of patients.
- LPS lipopolysaccharide
- JP-A-63-298 describes an immunodetection method based on the western blotting method using a monoclonal antibody against a membrane antigen protein of about 43 kilodaltons of Mycoplasma pneumoniae. .
- JP-A-62-148859 discloses a method for preparing a polyclonal antibody against an outer membrane protein of Haemophilus influenzae and the prepared antibody. Describes the diagnostic method.
- UK Patent Application No. 2172704 describes a protein of about 20 kilodaltons isolated from sodium cholate extract of outer membrane vesicles of Neisseria gonorrhoeae strain BS4 (NCTC 11922). It is disclosed that a hybridoma is prepared using this substance, and EP 419238A1 was prepared using Neisseria gonorrhoeae cultured cells as an immunogen and converted to a protein of about 14 kilodaltons. Describes a monoclonal antibody that can bind and a method for producing it. In addition, Canadian Patent Application No. 1220147 for the same Neisseria gonorrhoeae describes a detection method using a monoclonal antibody against LPS.
- the marker antigens used in these conventional technologies are the same functional molecules (for example, proteins with the same function, LPS or surface polysaccharide components) that are universally present in various microbial cells. It is not a unified approach of detecting a molecule that has changed for each species as a marker, but is based on the idea of detecting differences in antigenicity between bacterial species based on one molecule. The immunodiagnosis method used was not yet known.
- the present invention is a unified marker that enables ideal detection and immunodiagnosis of microorganisms.An antibody against the same molecule for each microorganism is used as one antigen, and in particular, the same functional component molecules in cells are used for all microorganisms to be detected. Antibodies that have been changed during the evolution of microorganisms, a method for detecting microorganisms using the antibodies that can cover almost all serotypes, a reagent kit for detecting microorganisms, and a specific antibody for detecting microorganisms It is intended to provide a method for producing the same.
- the present inventors have found a protein in which the same function is preserved in all microorganisms as a useful antigen protein. Usually, it is expected that such protein structural changes are extremely small. Surprisingly, however, the antigen epitope of the protein is specific to the species or genus of the microorganism, and antibodies against the protein have a variety that can be used to identify the species or genus of the microorganism. The target microorganism was found to be capable of detecting all its serotypes.
- Ribosomal Protein L7 / L12 is a protein with a molecular weight of about 13 kilodaltons, which is known to be a ribosomal protein essential for protein synthesis, and its amino acid sequence in several microorganisms such as Escherichia coli and Bacillus subtilis. Analysis is progressing, and homology of about 50% to 65% amino acid sequence among microorganisms has been confirmed.
- the present inventors have noted that although this molecule is similar between microorganisms, it partially has a structural portion such as an amino acid sequence unique to each microorganism, and by using an antibody against the protein, It was found that detection was possible for all serotypes that were specific to various microorganisms and within the same strain. Specifically For example, Haemophi lus influenzae, Streptococcus pneumoniae and ei s seri a gonorrhoeae t were used to develop immunological diagnostic techniques for microbial species using their specific antibodies. The present invention has been completed by finding that an antibody specific to the protein can be obtained in each of the microorganisms, and that the use of the antibody enables specific detection of each bacterium.
- the present invention relates to an antibody for detecting microorganisms, a method for detecting microorganisms using the same, a reagent kit for detecting microorganisms, and a method for producing a specific antibody for detecting microorganisms, as described below.
- Ribosomal Protein L7 / L12 of microorganisms obtained by genetic engineering techniques or isolation and purification from microorganisms, and its partial peptides or synthetic peptides corresponding to their partial peptides are used as immunogens. )).
- SEQ ID NOs: 1 and 2 are the DNA sequence and the corresponding amino acid sequence of the Ribosomal Protein L7 / L12 gene of Haemophilus influenzae.
- SEQ ID NOs: 3 and 4 are the DNA sequence of the Ribosomal Protein L7 / L12 gene of Helicobacter pylori and the corresponding amino acids.
- the sequence U number ⁇ "5 and 6 are the DNA sequence of the Ribosomal Protein L7 / L12 gene of Streptococcus pneumoniae and the corresponding amino acid sequence.
- Column numbers 7 and 8 are the Ribosomal Protein L7 / L12 genes of Neisseria gonorrhoeae SEQ ID NOS: 9 and 10 are the DNA sequence of the Ribosomal Protein L7 / L12 gene of Neisseria meningitidis and the corresponding amino acid sequence.
- PCR primer DNA used to obtain the Ribosomal Protein L7 / L12 gene from Haemophi lus influenzae SEQ ID NOs: 13 and 1 are the PCR primers used to obtain the Ribosomal Protein L7 / L12 gene from streptococcus pneumonoiae
- SEQ ID NOs: 15 and 16 are PCR primer DNAs used for obtaining Ribosomal Protein L7 / L12 iziz from Neisseria gonorrhoeae.
- SEQ ID NOs: 19 and 20 are Ribosomal Protein / L12 3 ⁇ 4 ⁇ obtained from stre tococcus pneumoniae.
- SEQ ID NOs: 21 and 22 are the DNA sequence of the Ribosomal Protein L7 / L12 gene and the corresponding amino acid sequence obtained from Neisseria gonorrhoeae.
- N-terminal an amino group
- C-terminal a carboxyl group terminal
- microorganisms refer to all microorganisms such as bacteria, yeasts, molds, actinomycetes, and rickettsiae.
- bacteria often cause problems in diagnosing microbial infectious diseases.
- the term "antibody specifically reactive with a microorganism” refers to an antibody that specifically reacts with a species or genus of a microorganism, but specifically reacts with a species of a microorganism in diagnosis of a microbial infectious disease. Antibodies will be particularly useful.
- the STD-causing microorganisms include Neisseria gonorrhoeae, Chlamydia trachomatis, Candida albicans, and TreDonema Da_l lidum. ), Ureaplasma urealyticum and the like, but are not limited to these microorganisms.
- the causative microorganisms of the respiratory system infection include Haemophilus influenzae (Haemophi lus ⁇ ⁇ uenzae), Streptococcus pneumoniae (Streptococcus pneumoniae; Kneum pneumonia (chlamydia pneumoniae), Mycoplasma pneumoniae (Mycoplasma pneumoniae), and pneumonia (Klebsiel la pneumoniae), Staphylococcus aureus, Pseudomonas aeruginosa, Group A ⁇ (streptococcus sp.GroupA) ⁇ 3 ⁇ 4 (Mycobacterium tuberculosi s), Legionella (Legionel la pneumophi) la) ⁇ Fungus of the genus Aspe Resinoleth
- an antibody refers to a polyclonal antibody or a monoclonal antibody, and can be produced using the full length of the liposome protein or a partial peptide thereof.
- the length of the peptide for preparing the antibody is not particularly limited, but in the case of an antibody against the Ribosomal Protein L7 / L12 protein, it is sufficient that the length be characterized by this protein, and more preferably 5 amino acids or more, particularly Preferably, a peptide having 8 or more amino acids may be used.
- This peptide or full-length protein is cross-linked to a carrier protein such as KLH (keyhole-l impet hemocyanin) or BSA (bovine serum albumin) as it is, or after inoculation with an adjuvant as needed, and the serum is recovered.
- a carrier protein such as KLH (keyhole-l impet hemocyanin) or BSA (bovine serum albumin)
- KLH keyhole-l impet hemocyanin
- BSA bovine serum albumin
- an antiserum containing an antibody (polyclonal antibody) that recognizes the Ribosomal Protein L7 / L12 protein can be obtained. Further, the antibody can be purified from the antiserum and used.
- the animals to be inoculated include sheep, horses, goats, goats, mice, rats, and the like. Particularly, for producing polyclonal antibodies, sheep, goats, etc. are preferable.
- a monoclonal antibody can be obtained by a known method for producing hybridoma cells.
- a mouse is preferred.
- a protein obtained by fusing a full-length protein or a partial peptide of 5 or more amino acids, preferably 8 or more residues with GST (daltathione-S-transferase) or the like is purified or left unpurified as an antigen. It can also be used.
- An antibody against the Ribosomal Protein L7 / L12 protein that can be used as the marker antigen of the present invention can be obtained by the following three methods or other similar methods, but is not limited to these methods. .
- the target antibody can be obtained by synthesizing a peptide fragment of about 5 to 30 amino acids in a region with low affinity and preparing a polyclonal or monoclonal antibody using the peptide fragment as an immunogen.
- the full-length sequence of the gene can be obtained by using a conventional gene manipulation technique such as gene amplification by a PCR method using a DNA sequence at both ends of the known gene as a probe and a hybridization method using a homologous partial sequence as a ⁇ -type probe. Can be obtained.
- a fusion gene with another protein gene is constructed, and the fusion gene is introduced into a host by a known gene transfer method using Escherichia coli or the like as a host, expressed in a large amount, and then used as a fusion protein.
- the protein antigen of interest can be obtained by purifying the expressed protein by an antibody affinity column method or the like. In this case, since the full-length protein of Ribosomal Protein L7 / L12 serves as an antigen, obtaining an antibody against an amino acid portion preserved between microorganisms does not meet the purpose of the present invention.
- a hybridoma that produces a monoclonal antibody is obtained by a known method, and a target antibody is obtained by selecting a clone that produces an antibody that reacts only with the relevant microorganism. be able to.
- the amino acid sequence of Ribosomal Protein L7 / L12 is 50-60% homologous between bacterial species, indicating that the amino acid sequence is homologous.
- the protein gene can be easily obtained by using a general gene manipulation technique such as gene amplification of a specific sequence portion by PCR or a hybridization method using a homologous partial sequence as a type I probe. it can.
- a fusion gene with another protein gene is constructed, and the fusion gene is inserted into a host by Escherichia coli or the like using a known gene transfer technique and expressed in a large amount.
- the target protein antigen can be obtained by purifying the expressed protein by a two-one column method or the like. This place Since the full-length protein of the combined Ribosomal Protein L7 / L12 serves as an antigen, obtaining an antibody against an amino acid portion conserved between microorganisms does not meet the purpose of the present invention. Therefore, for the antigen obtained by this method, a hybridoma producing a monoclonal antibody is obtained by a known method, and a clone producing an antibody that reacts only with the relevant microorganism is selected. You can get antibodies.
- Ribosomal Protein L7 / L12 when the amino acid sequence of Ribosomal Protein L7 / L12 is unknown, another method is to use 5 to 30 amino acid sequences of the known Ribosomal Protein L7 / L12 that correspond to the consensus sequence conserved between microorganisms.
- a synthetic peptide of amino acid is prepared, a polyclonal antibody or a monoclonal antibody is prepared by a known method for the peptide sequence, and the desired microbial cell lysate is purified by affinity column chromatography using the antibody.
- highly purified Ribosomal Protein L7 / L12 protein can be obtained.
- the protein is purified by a known purification method such as ion exchange chromatography, hydrophobic chromatography, or gel filtration, and then subjected to a method such as western blotting using an antibody prepared.
- the purified protein can be obtained by identifying the elution fraction of Ribosomal Protein L7 / L12 protein. Based on the obtained purified Ribosomal Protein L7 / L12 protein antigen, obtain a hybridoma or polyclonal antibody by a known method and select a hybridoma or polyclonal antibody that specifically reacts with the target microorganism as in b). By doing so, the desired antibody can be obtained.
- Antibodies specific to various microorganisms according to the present invention obtained by the above methods a) to c) are, for example, a coagulation reaction in which the antibodies are adsorbed on polystyrene latex particles, and an ELISA method which is a known technique performed in a microtiter plate. All known methods, such as the existing immunochromatography method, colored particles or particles having a color-forming ability, or sandwiches using magnetic particles coated with a capture antibody together with the antibody labeled with an enzyme or a fluorescent substance. Reagents for detection of microorganisms of various purposes by utilizing the immunoassay technique A kit can be provided.
- the microorganism detection method using an antibody includes, for example, an agglutination reaction in which the antibody is adsorbed on polystyrene latex particles, an ELISA method, which is a known technique performed in a microtiter plate, an existing immunochromatography method, a colored particle or a colorant.
- an agglutination reaction in which the antibody is adsorbed on polystyrene latex particles
- an ELISA method which is a known technique performed in a microtiter plate
- an existing immunochromatography method a colored particle or a colorant.
- This corresponds to a detection method using a known immunoassay technique such as sandwich or the like using magnetic particles or the like coated with a capture antibody together with particles or the antibody labeled with an enzyme or a fluorescent substance.
- a so-called detection method based on the principle of light interference in which an antibody reaction is performed on an optical thin film formed of silicon, silicon nitride or the like described in JP-T-7-509565, etc.
- Optical immunoassays are useful as highly sensitive detection methods.
- methods for extracting intracellular marker antigens from microorganisms required for the detection method include various surfactants such as Triton X-100 (Tween-20), Tween-20, and the like.
- a known method of crushing cell structures such as a method using an extraction reagent using a bacterium, an enzyme treatment method using an enzyme such as an appropriate protease, or crushing a microbial cell by a physical method, may be used. It is desirable to set the optimal extraction conditions with the reagent for each microorganism by the combination.
- the reagent kit for detecting a microorganism using an antibody in the present invention corresponds to a reagent kit for detection using the detection method.
- the amino acid sequence and DNA sequence of Ribosomal Protein L7 / L12 protein of this bacterium are obtained from a database. And so on.
- the amino acid sequence and the DNA sequence of Ribosomal Protein L7 / L12 of Haemophi lus influenzae are shown in SEQ ID NOs: 1 and 2 in the Sequence Listing.
- the amino acid sequence of the Ribosomal Protein L7 / L12 protein is also known.
- the amino acid sequence of the Ribosomal Protein L7 / L12 protein is compared with that of the same protein of Helicobacter milori shown in SEQ ID NOs: 3 and 4 in the Sequence Listing.
- a synthetic peptide of 5 to 30 amino acids can be synthesized, and a polyclonal antibody or a monoclonal antibody specific to Haemophilus influenzae can be prepared against the peptide.
- PCR primers based on the N-terminal and C-terminal sequences from the MA sequence of the Ribosomal Protein L7 / L12 protein of Haemophi lus influenzae for example, the PCR primers shown in SEQ ID NOs: 11 and 12 in the Sequence Listing are designed, and their homology is determined.
- a genomic DNA extracted from cultured cells of Haemophilus influenzae is used as a material to obtain a DNA fragment to be amplified by PCR or the like, and DNA sequence information of the fragment is obtained.
- the full-length gene of Ribosomal Protein L7 / L12 protein of Haemophi lus influenzae can be obtained.
- the obtained Ribosomal Protein L7 / L12 gene of Haemophi lus influenzae constitutes a fusion protein gene with, for example, GST etc., constructs an expression vector using an appropriate expression plasmid, and then transforms E. coli or the like to transform the protein. White matter can be expressed in large quantities. After culturing an appropriate amount of the transformed E. coli and purifying the recovered cell lysate with an affinity column using GST, a fusion protein of Haemophilus influenzae Ribosomal Protein L7 / L12 protein and GST can be obtained. .
- This protein is used as is, or after cleavage of the GST portion with a protease or the like, a plurality of hybridomas are established by a method known as an antigen protein, and the cells containing Haemophi lus influenzae cells are lysate of the cells or Ribosomal of Haemophi lus influenzae.
- an antibody that shows a specific reaction to the Protein L7 / L12 protein it is also possible to obtain the desired specific monoclonal antibody.
- Ribosomal Protein L7 / L12 protein are described in databases etc. It is known.
- the amino acid sequence and DNA sequence of Ribosomal Protein L7 / L12 of Streputococcus pneumoniae are shown in SEQ ID NOs: 5 and 6 in the Sequence Listing.
- a PCR primer based on the N-terminal and C-terminal sequences from the DNA sequence of Ribosomal Protein L7 / L12 protein of Streputococcus pneumoniae for example, SEQ ID NO:
- Hybridoma AMSP-2 which produces a specific monoclonal antibody, was submitted to the Ministry of International Trade and Industry, Japan, on November 28, 1999 under the accession number of FERM BP-6807. As an international deposit.
- Neisseria gonorrhoeae which is a causative bacterium of gonorrhea and whose diagnostic significance is recognized as a representative causative bacterium of STD
- most of its DNA and amino acid sequences have recently been obtained from the Neisseria gonorrhoeae genome project at the University of Otarahoma, USA. And the DNA sequence of the bacterium is published on the Internet.
- PCR primers based on the N-terminal and C-terminal sequences from the fragile sequence of Ribosomal Protein L7 / L12 protein of Neisseria gonorrhoeae, for example, SEQ ID NO: 15 and By designing the PCR primers shown in Fig. 16, it is possible to obtain an antibody specific to Neisseria gonorrhoeae, which uses the whole or a part of Ribosomal Protein L7 / L12 protein of Neisseria gonorrhoeae as an antigen, in exactly the same manner.
- the amino acid sequence that differs in the amino acid sequence at the 115th position from the N-terminal is Neisseria gonorrhoeae.
- Nei sseria meningit idi s there is only one amino acid difference that is glutamic acid.
- the Ribosomal Protein L7 / L12 protein antibody of Neisseria gonorrhoeae which can detect Neisseria gonorrhoeae species-specifically, contains the 115th alanine from the N-terminal of the corresponding Ribosomal Protein L7 / L12 protein and contains it. It is definitely determined that the antibody recognizes the amino acid region as an epitope.
- Antibodies prepared according to the present invention include known measurement techniques such as agglutination reaction in which the antibody is adsorbed on polystyrene latex particles, ELISA technique known in the art of microtiter plates, existing immunochromatography, The present invention can be used for all known immunoassay techniques such as a sandwich assay using colored particles or particles having a coloring ability, or magnetic particles coated with a capture antibody together with the antibody labeled with an enzyme or a fluorescent substance.
- the antibody prepared according to the present invention can function as a capture antibody that captures the antigen protein in a solid phase or a liquid phase in all immunoassay techniques, and at the same time, uses an enzyme such as peroxidase or al lipophosphatase. Modification by a known method can function as a so-called enzyme-labeled antibody.
- Haemophi lus influenzae ATCC933 (IID984) Co., Ltd. (sale from the Institute of Medical Science, University of Tokyo, purchase) after the inoculated appropriate amount on chocolate agar, C0 2 I Nkyubeta in one in 37 ° C, C0 2 0. 5 % Incubate under the conditions for 24 hours.
- the grown colonies are suspended in TE Buffer (manufactured by Wako Pure Chemical Industries, Ltd.) so that the final colonies are around 5 ⁇ 10 9 CFU / ml. Transfer about 1.5 ml of this to a microcentrifuge tube, centrifuge at lOOOOrpm for 2 minutes, and discard the supernatant. Resuspend the pellet in 567 1 TE Buffer.
- PCR polymerase chain reaction
- This mixture was subjected to 5 cycles of 95 ° C for 1 minute, 50 ° C for 2 minutes, and 72 ° C for 3 minutes using TaKaRa PCR Thermal Cycler 480, and then 95 ° C for 1 minute, 60 ° C for 2 minutes, and 72 ° C for 2 minutes. 25 cycles of 3 minutes at ° C.
- a portion of this PCR product was electrophoresed in a 1.5% agarose gel, stained with ethidium mouth mouth (manufactured by Nippon Gene Co., Ltd.), observed under ultraviolet light, and approximately 400 bp of cDNA was amplified. It was confirmed.
- This vector can function as an expression vector for a target molecule capable of expressing a fusion protein with a GST protein by incorporating a target gene fragment into an appropriate restriction enzyme site.
- the vector pGEX-4T-1 was mixed with the preceding DNA in a molar ratio of 1: 3, and the DNA was incorporated into the vector using T4 DNA ligase (Invitrogen).
- L_Broth manufactured by Takara Shuzo
- One of the five clones obtained has sequence homology with the probe used for PCR, and is very similar to the sequence of the Ribosomal Protein L7 / L12 gene of other microorganisms, such as Neisseria gonorrhoeae. DNA sequence was found. The entire nucleotide sequence and the corresponding amino acid sequence of the structural gene portion were as shown in SEQ ID NO: 17 and 18 in the Sequence Listing. This gene fragment encodes the gene for Ribosomal Protein L7 / L12 protein of Haemophi lus influenzae.
- Escherichia coli incorporating the expression vector was cultured in LB medium at 50 ml 37 ° C for 1 ⁇ . 500 ml of 2 ⁇ TY medium was warmed at 37 ° C. for 1 hour. 50 ml of the 1 ⁇ -cultured E. coli solution was placed in 500 ml of the above-mentioned medium. After 1 hour, 100 mM isopropyl After culturing for 4 hours, the cells were collected and centrifuged at 7000 rpm for 10 minutes in 250 ml aliquots in a centrifuge tube. The supernatant was discarded, and the cells were dissolved in 25 ml of Lysis buffer containing 50 mM Tris-HCl (pH 7.4) and 25% sucrose.
- NP_40 Nonidet P-40
- MgCl 2 125 1 1M MgCl 2 125 1 were added and transferred to a plastic tube. Sonication was carried out in ice-cooling for 1 minute X 5 times, and the supernatant was collected after centrifugation at 12000 rpm for 15 minutes.
- the power column was washed with a washing solution containing 20 mM Tris buffer pH 7.4, 4.2 mM MgCl 2 , and ImM dithiothreitol (DTT) for two beds of volume.
- a washing solution containing 20 mM Tris buffer pH 7.4, 4.2 mM MgCl 2 , and ImM dithiothreitol (DTT) for two beds of volume.
- DTT ImM dithiothreitol
- the myeloma cells used for cell fusion were cultured in RPMI1640 medium containing 10% fetal calf serum (FCS) using NS-1 cell line, and 0.12 mM azaguanine was added 2 weeks before cell fusion. After culturing for 1 week in RPMI1640 medium containing 5 / g / ml MC-210 and 10% FCS, those cultured for another week in RPMI1640 medium containing 10% FCS were used.
- FCS fetal calf serum
- the cells were washed with a washing solution (T ⁇ veen20 0.02%, PBS), and 100 l of the culture solution of the fused cells was added thereto. After reacting at room temperature for 2 hours, the supernatant was removed, and the cells were washed with the washing solution.
- 100 ng / ml of peroxidase-labeled goat anti-mouse IgG antibody solution was added at 100 / zl, the reaction was carried out at room temperature for 1 hour, the supernatant was removed, and the plate was washed with a washing solution, and then the TMB solution (KPL) was added to 100 / zl. The reaction was stopped by adding 1N sulfuric acid 100 / l after color development, and the absorbance at 450 nm was measured.
- Protein L7 / L12 protein was found to contain antibodies.
- the cells in the positive well were collected and cultured in a HAT medium in a 24-well plastic plate. Diluted 50 / zl Cultured fusion medium with HT medium so that such approximately 20 cells / ml cell number, a mouse thymus of 6 week old which were suspended in HT medium 106 cells and 96-well culture plates Then, the cells were cultured at 37 ° C for 2 weeks under 7% CO 2 conditions. The antibody activity in the culture supernatant was similarly assayed by the above-mentioned ELISA method, and cells positive for reaction with Ribosomal Protein L7 / L12 protein were collected. Further, the same dilution assay and clawing operation were repeated to obtain a total of five clones of the hybridoma HIRB-1 to HIRB-5.
- cells subcultured using RPMI 1640 medium were intraperitoneally injected into Balb / C mice to which 0.5 ml of pristane was injected intraperitoneally two weeks ago. Six injections (in PBS) were made. Three weeks later, ascites was collected, and the centrifugal supernatant was obtained.
- the obtained antibody-containing solution is absorbed on a Protein A column (5 ml bed, Pharmacia), washed with PBS in a 3-bed volume, eluted with a pH 3 citrate buffer, and the antibody fraction is collected to produce each hybridoma. Monoclonal antibody was obtained.
- the sandwich assay is used for antibody evaluation, and the prepared monoclonal antibody is chemically bound to peroxidase to form an enzyme-labeled antibody. Used as
- enzyme labeling was performed using horseradish peroxidase (Sigma grade VI) and binding was performed using the reagent S-acetylthioacetic acid N-hydroxysuccinimide, as described in Analytical Bio-chemistry 132 (1983), 68-73. The method was followed.
- a 10 ⁇ g / ml solution of a commercially available anti-Haemophilus influenzae polyclonal antibody (Biosag, Persian) dissolved in PBS containing 0.05% sodium azide was diluted in 10 ⁇ g / ml concentrations into 96-well plates separately. And adsorbed 1 ⁇ at 4 ° C.
- Ribosomal Protein L7 / L12 1B from streptococcus pneumoniae et al., large-scale expression and purification of the protein in Escherichia coli, and production of monoclonal antibodies against the protein.
- PCR was performed using 10 ng of this genomic DNA. PCR used Taq polymerase (Takara Shuzo Co., Ltd., code R001A). 5 ⁇ l of the buffer attached to the enzyme, 4 ⁇ l of the dNTP mixture attached to the enzyme, synthetic oligonucleotide C shown in SEQ ID NO: 13 and synthetic oligonucleotide D shown in SEQ ID NO: 14 in the sequence listing, respectively 200 pmol was added to make a final volume of 501.
- Taq polymerase Takara Shuzo Co., Ltd., code R001A
- This mixture was subjected to 5 cycles of 95 ° C for 1 minute, 50 ° C for 2 minutes, and 72 ° C for 3 minutes using the TaKaRa PCR Thermal Cycler 480, and then 95 ° C for 1 minute, 60 ° C for 2 minutes, and 72 ° C for 2 minutes. 25 cycles of 3 minutes at ° C.
- a portion of this PCR product was electrophoresed in a 1.5% agarose gel, stained with ethidium Mabuchi Mide (manufactured by Nippon Gene Co., Ltd.), and observed under ultraviolet light to confirm that approximately 400 bp cDNA had been amplified. did.
- the vector pGEX-6P-1 and the above DNA were mixed at a molar ratio of 1: 5, and the DNA was incorporated into the vector using T4 DNA ligase (Invitrogen).
- the vector pGEX-6P-1 incorporating the DNA was transfected into Escherichia coli One Shot Competent Cells (Invitrogen), and ampicillin was used.
- L-Broth (Takara Shuzo) semi-solid medium containing 50ii g / ml, allowed to stand at 37 ° C for about 12 hours, and the colonies that appeared were randomly selected. Inoculate 2 ml of L-Broth liquid medium containing the same concentration of ampicillin, shake and culture at 37 ° C for about 8 hours, collect the cells, and use Wizard Miniprep.
- PRISM Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems) was used.
- a 0.5 ml microtube add 9.51 reaction stock solution, 4.0 / l of 0.8 ⁇ 1 / ⁇ 1 ⁇ 7 promoter primer (GIBC0 BRL) and 6.5 / i1 of 0.16 ⁇ g / ⁇ 1 sequence ⁇ Add ⁇ and mix, overlay with 100 1 mineral oil, perform 25 cycles of PCR amplification reaction at 96 ° C for 30 seconds, 55 ° C for 15 seconds, and 60 ° C for 4 minutes for 25 cycles. Incubated at C for 5 minutes.
- One of the seven clones obtained has sequence homology with the probe used for PCR, and is very similar to the sequence of the Ribosomal Protein L7 / L12 gene of other microorganisms, for example, Neisseria gonorrhoeae. DNA sequence was found. The entire nucleotide sequence and the corresponding amino acid sequence of the structural gene portion were as shown in SEQ ID NO: 19 and 20 in the Sequence Listing. This gene fragment apparently encodes the gene of Ribosomal Protein L7 / L12 protein of Streptococcus pneumoniae.
- Escherichia coli harboring the expression vector was cultured in a double concentration of YT medium at 50 ml at 37 ° C for 1 hour. 450 ml of 2X YT medium was warmed at 37 ° C for 1 hour. 1 ⁇ 50 ml of the cultured E. coli culture was placed in 450 ml of the aforementioned medium. After culturing at 37 ° C for 1 hour, 100 ⁇ l of 500 mM IPTG was added, and the cells were collected after culturing at 25 ° C for 4 hours, centrifuged at 5,000 rpm for 20 minutes in 250 ml centrifuge tubes. The supernatant was discarded, and the cells were dissolved in 25 ml of Lysis buffer containing 50 mM Tris-HCl pH 7.4 and 25% sucrose.
- the supernatant was adsorbed to a daltathione sepharose (Pharmacia) column conditioned with PBS.
- the column was washed with PBS for three times the amount of polytetrame.
- elution was performed with 50 mM Tris-HCl 8.0 containing 10 mM daltathione, and the protein content in the fractionated fraction was detected by a dye binding method (Bradford method; BioRad) to obtain a main fraction.
- the main fraction was dialyzed three times against 3 L PBS.
- the GST portion was separated from the Ribosomal Protein L7 / L12 protein portion.
- reaction solution was passed through a glutathione sepharose column conditioned with PBS, and the permeate was collected. Further, PBS was flowed through one bed volume, and this was also collected. The purity of the obtained purified Ribosomal Protein L7 / L12 protein was approximately 90% as confirmed by electrophoresis, and sufficient purity as an immunogen was secured.
- Streptococcus pneumoniae Ribosomal Protein L7 / L12 protein antigen 100 ⁇ g was dissolved in PBS (2001), Freund's complete adjuvant (2001) was added, mixed, and emulsified.
- PBS PBS
- Freund's complete adjuvant 2001
- the same emulsion antigen was injected intraperitoneally.
- Furthermore 10 weeks, and 14 weeks later, a two-fold concentration of antigen emulsion was injected intraperitoneally, and three days after the final immunization. Later, the spleen was removed and subjected to cell fusion.
- the myeloma cells used for cell fusion were cultured in RPMI1640 medium containing NS-1 cell line, and 0.1 weeks after cell fusion, 0.13 mM azaguanine, 0.5 ⁇ g / ml MC -After culturing in RPMI1640 medium containing 210 and 10% FCS for 1 week, and further culturing in RPMI1640 medium containing 10% FCS for 1 week, used.
- the cells in the positive well were collected and cultured in a HAT medium in a 24-well plastic plate. After mixing the fusion medium was cultured and diluted with HT medium so that such approximately 20 cells / ml cell number, with 10 6 murine thymocytes 6 week old suspended in HT medium and a 96-well culture plates , 7% C0 2 conditions and 2 weeks cultured at 37 ° C.
- the antibody activity in the culture supernatant was similarly assayed by the aforementioned ELISA method, and cells positive for reaction with the Ribosomal Protein L7 / L12 protein were collected. Further, the same dilution assay and clawing operation were repeated to obtain a total of 4 clones of the hybridomas AMSP-1 to AMSP-4.
- cells subcultured using RPMI1640 medium were cultured in 25 cm 2 culture flasks at 2 ⁇ 10 5 cells / ml, 3.3 ⁇ 10 5 cells and 5 ⁇ 10 5 cells / ml.
- the volume was diluted to about 5 ml with serum-free medium.
- 7% C0 2, 37 ° C at grown for 3-5 days, among flasks in cell growth was observed, select the one original number of cells the least, finally 2 X 10 5 cells / ml
- the same operation was repeated until the diluted cells grew to 2 ⁇ 10 6 cells / ml in 3 to 4 days, and the cells were adapted to a serum-free medium.
- cloning was performed in a 96-well plate for bacterial culture, and cells that grew rapidly and had high antibody titers were selected.
- the selected cells grown in a 24-well plate were diluted with a serum-free medium to a total volume of 10 ml in a 25 cm 2 culture flask at a concentration of about 2 ⁇ 10 5 cells / ml. This was grown to 7% C0 2, 37 ° and incubated for 3-4 days at C 1 X 10 6 cells / ml, 1 X 10 6 cells were grown similarly in 75 cm 2 culture flasks / ml, a 100ml Transferred to bottle for mass culture.
- a serum-free medium 100 ml of a serum-free medium was added thereto, and the mixture was cultured at 37 ° C for 2 days with stirring. Divide this culture into 4 tubes, add 100 ml of serum-free medium each, and incubate for 2 days, add 400 ml of serum-free medium each, and further culture for about 6 days, collect the culture, and centrifuge at 10,000 rpm for 5 minutes for the purpose. A culture supernatant containing the antibody to be used was obtained. The culture supernatant was stored at 4 ° C after addition of 0.1% sodium azide.
- a reaction substrate was prepared by reacting an antibody for capture on a silicon wafer having a thin layer of silicon nitride, and an antigenic substance, that is, an extract of microorganisms, was reacted for a certain period of time. After that, the captured antigen is further reacted with the enzyme-labeled antibody (amplification reagent), and finally the antigen-antibody reaction can be visually determined by the light interference color due to the thin film precipitation generated by adding the substrate solution. This is the way to go. 2.8
- Monoclonal antibodies prepared was used as a ca p ture antibody immobilized on a silicon N'weha with thin layers of silicon nitride 0IA method was evaluated.
- the detect antibody used was an AMGC-1 monoclonal antibody capable of non-specifically reacting with Ribosomal Protein L7 / L12 proteins of various microorganisms described in Reference Examples, which was enzymatically labeled with peroxidase. That is, the enzyme labeling uses horseradish peroxidase (Sigma grade VI) and the binding uses the reagent S-acetylthioacetic acid N-hydroxysuccinimide and is described in Analytical Bio-chemistry 32 (1983), 68-73. I went according to the method.
- the monoclonal antibody in PBS containing 0.05% sodium azide was diluted to a concentration of lO ⁇ ug / ml with 0.1M HEPES pH 8.0. It was added to a silicon wafer and reacted at room temperature for 30 minutes, washed with distilled water, and used.
- An antigen solution obtained by subjecting a suspension of various microorganisms to extraction with 0.5% concentration Triton X-100 at room temperature for 5 minutes is added to the suspension, and the mixture is reacted at room temperature for 15 minutes.
- 20 mg / rnl of Add 15 1 peroxidase-labeled AMGC1 antibody perform reaction at room temperature for 10 minutes, wash with distilled water, add substrate solution (KPL) at 15 / xl each, react at room temperature for 5 minutes, wash with distilled water, and then detect signal was visually determined as the intensity of the light interference color.
- Nei sseri a gonorrhoeae IID821 strain (sale from the University of Tokyo Institute of Medical Science, purchase) the after inoculated appropriate amount onto chocolate agar at 37 ° C, C0 2 0. 5 % condition in C0 2 incubator 24 Cultured for hours. The grown colonies eventually to be around 5 X l0 9 CFU / ml suspended in TE Buffer.
- This mixture was subjected to 5 cycles of 95 ° C for 1 minute, 50 ° C for 2 minutes, and 72 ° C for 3 minutes using TaKaRa PCR Thermal Cycler 480, and then 95 ° C for 1 minute, 60 ° C for 2 minutes, and 72 ° C for 2 minutes. 25 cycles of 3 minutes at ° C.
- a portion of this PCR product was electrophoresed in a 1.5% agarose gel, stained with ethidium mouth mouth (manufactured by Nippon Gene), observed under ultraviolet light, and approximately 400 bp of cDNA was amplified. It was confirmed. After digestion with restriction enzymes BamHI and Xhol, electrophoresis was performed in a 1.5% agarose gel.
- the nucleotide sequence of the inserted DNA fragment was determined using a fluorescent theta-encer manufactured by Applied Biosystems. Preparation of sequence sample
- PRISM Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems) was used.
- reaction stock solution 9.51, 0.8 ⁇ 1 / ⁇ 1 of 4.0 / i 1 ⁇ 7 promoter and primer (Manufactured by GIBCO BRL) and 6.5 ⁇ l of 0.16 ⁇ g / ⁇ 1 DNA for sequence ⁇ ⁇ DNA were added and mixed, and 100 ⁇ 1 of mineral oil was overlaid.
- the PCR amplification reaction was performed for 25 cycles, each cycle consisting of 15 ° C for 15 seconds and 60 ° C for 4 minutes, and incubated at 4 ° C for 5 minutes.
- One of the five clones obtained has sequence homology to the probe used for PCR and is very similar to other microorganisms, for example, Riemosomal Protein L7 / L12 gene arrangement J 'of Haemophi lus influenzae. Similar DNA sequences were found.
- a hybridoma GCRB-3 strain producing a monoclonal antibody against Ribosomal Protein L7 / L12 protein was obtained.
- the obtained antibody-containing solution is adsorbed on a ProteinA column (5 ml bed, manufactured by Pharmacia), washed with PBS in a 3-bed volume, and eluted with a pH citrate buffer.
- the antibody fraction is recovered and the hybridoma is recovered.
- the monoclonal antibody to be produced was obtained.
- the monoclonal antibody derived from the GCRB-3 hybridoma was evaluated by ELISA.
- the antibody was evaluated by the sandwich assay method, and the prepared monoclonal antibody was used as an enzyme-labeled antibody by chemically binding to peroxidase.
- the enzyme label is horseradish peroxidase (Sigma grade VI) and the reagent is N-hydroxysuccinimide S-acetylthioacetate for binding, as described in Analytical Bio-chemistry 32 (1983), 68-73.
- the procedure was performed according to the method. In an ELISA reaction
- a 96-well plate was prepared by diluting a commercially available anti-gonococcal polyclonal antibody (Vagilostat, Inc.) dissolved in PBS containing 0.05% sodium azide at a concentration of 10 / xg / ml into a 96-well plate. Dispensed separately and adsorbed 1 ⁇ at 4 ° C.
- the hybridoma GCRB-3 was used as an enzyme-labeled antibody. If a monoclonal antibody of interest was used, the tested Neisseria
- Neisseria gonorrhoeae IID821 strain (sale from the University of Tokyo Institute of Medical Science, purchase) was inoculated appropriate amount of chocolate agar on, in C0 2 incubator for 24 hours at 37 ° C for at C0 2 concentration of 0.5% Conditions .
- PCR was performed using 10 ng of this genomic DM. PCR used Taq polymerase (Takara Shuzo Co., Ltd., code R001A). Due to the similarity between 5 ⁇ l of the buffer attached to the enzyme, 4 ⁇ l of the dNTP mixture attached to the enzyme, and the Ribosomal Protein L7 / L12 DNA sequence of other bacteria, the Internet information (Oklahoma University, Neisseria gonorrhoeae genome) The sequence was designed from Neisseria gonorrhoeae Ribosomal Protein L7 / L12 DNA sequence 3 ⁇ 4rb and was obtained from the project public genomic DNA information. 200 pmol of each of the synthetic oligonucleotides F shown in SEQ ID NO: 16 in the column list was used as a probe to give a final volume of 501.
- This mixture was subjected to 5 cycles of 95 ° C for 1 minute, 50 ° C for 2 minutes, and 72 ° C for 3 minutes using TaKaRa PCR Thermal Cycler 480, and then 95 ° C for 1 minute, 60 ° C for 2 minutes, 25 cycles of 3 minutes at 72 ° C were performed.
- a portion of this PCR product was subjected to electrophoresis in a 1.5% agarose gel, stained with ethidium Mabuchi Mide (manufactured by Nippon Jin Co., Ltd.), observed under ultraviolet light, and about 400 bp cDNA was amplified. I confirmed that.
- the vector can function as an expression vector for a target molecule capable of expressing a fusion protein with a GST protein by incorporating a target gene fragment into an appropriate restriction enzyme site.
- the vector pGEX-6P-1 and the above DNA are mixed at a molar ratio of 1: 5, and the mixture is converted into a vector using T4 DNA ligase (Invitrogen). DNA was incorporated.
- the vector pGEX-6P-1 incorporating the DNA was transfected into Escherichia coli One Shot Competent Cells (manufactured by Invitrogen), and ampicillin was used.
- the aqueous layer was subjected to three extractions with phenol / chloroform.
- ⁇ of sodium 3 ⁇ acetate ( ⁇ (5.2) and 300 ⁇ l of ethanol were added and stirred, followed by centrifugation at room temperature at 14000 rpm for 15 minutes to collect the precipitate. After washing the precipitate with 75% ethanol, it was left standing under vacuum for 2 minutes and dried to prepare a sample for sequencing.
- the sequence sample is 4 ⁇ l of 10 mM
- Escherichia coli harboring the expression vector was cultivated in 50 ml 37 ° C 1 1 in a double concentration of YT medium. 450 ml of 2X YT medium was warmed at 37 ° C for 1 hour. 1 ⁇ 50 ml of the cultured E. coli culture was placed in 450 ml of the aforementioned medium. After culturing at 37 ° C for 1 hour, 100 // 1 of 500 mM IPTG was added, and the cells were collected after culturing for 4 hours at 25 ° C, and 250 ml of each was centrifuged at 5000 rpm for 20 minutes in a centrifuge tube. The supernatant was discarded, and the cells were dissolved in 25 ml of Lyss buffer containing 50 mM Tris-HCl pH 7.4 and 25% sucrose.
- the supernatant was adsorbed to a daltathione sepharose (Pharmacia) column conditioned with PBS.
- the column was washed with PBS for 3 bead polymums.
- elution was performed with 50 mM Tris-HCl 8.0 containing 10 mM daltathione, and the protein content in the fractionated fraction was detected by the dye binding method (Bradford method; BioRad), and the main fraction was obtained. .
- the main fraction was dialyzed three times against 3 L PBS.
- reaction solution was passed through a glutathione sepharose column conditioned with PBS, and the permeate was collected. Further, PBS was flown through a one-bed volume and this was also collected.
- the purity of the obtained purified Ribosomal Protein L7 / L12 was approximately 90%, as confirmed by electrophoresis, and it was sufficient to ensure sufficient purity as an immunogen. Came.
- the myeloma cells used for cell fusion were cultured in RPMI1640 medium containing 1096 FCS using NS-1 cell line, and 0.13 mM azaguanine and 0.1 Sii g / ml were obtained from 2 weeks before cell fusion. After culturing for one week in RPMI1640 medium containing MC-210 and 10% FCS, the culture was further used for one week in RPMI1640 medium containing 10% FCS. To the mixed cell sample, add 30ml of 50ml RPMI1640 medium kept at 37 ° C, centrifuge at 1500rpm, remove the supernatant, add 1ml of 50% polyethylene glycol kept at 37 ° C, treat with vigorous stirring for 2 minutes, then 37 ° C. 10 ml of RPMI1640 medium kept warm was added to the solution C, and the solution was vigorously stirred and mixed for about 5 minutes while sucking and discharging the solution with a sterile pipe.
- the cells in the positive well were collected and cultured in a HAT medium in a 24-well plastic plate. Dilute the cultured fusion medium with HT medium so that the cell number becomes about 20 cells / ml, and add 50 ⁇ l of 6-week-old mouse thymus cells suspended in ⁇ medium to 10 6 cells in a 96-well culture plate. in after mixing, 7% C0 2 conditions and 2 weeks cultured at 37 ° C.
- the antibody activity in the culture supernatant was similarly assayed by the aforementioned ELISA method, and cells positive for reaction with the Ribosomal Protein L7 / L12 protein were collected. Further, the same dilution assay and cloning operation were repeated to obtain a total of 4 clones of hybridomas AMGC-5 to 8.
- Monoclonal antibodies were produced and recovered according to a standard method using the positive hybridoma cells obtained as described above.
- cloning was performed in a 96-well plate for bacterial culture, and cells that grew rapidly and had high antibody titers were selected.
- the selected cells were diluted in serum-free media so that 2 X 10 approximately 5 cells / ml to those grown in 24 well plates in 25 cm 2 culture flasks The total volume was 10 ml. This was grown to 7% C0 2, 37 ° C in cultured 3-4 days 1 X 10 6 cells / ral, 1 X 10 6 cells were grown similarly in 75 cm 2 culture flasks / ml, a 100ml Transferred to bottle for mass culture. 100 ml of a serum-free medium was added thereto, and the mixture was cultured at 37 ° C for 2 days with stirring.
- the monoclonal antibodies derived from these four strains of hybridomas were evaluated by the 0IA method described in JP-T-Hei 7-509565.
- a reaction substrate was prepared by reacting an antibody for capture on a silicon wafer having a thin layer of silicon nitride, and an antigenic substance, that is, an extract of microorganisms, was reacted for a certain period of time. After that, the captured antigen is further reacted with the enzyme-labeled antibody (amplification reagent), and finally the antigen-antibody reaction can be visually determined by the light interference color due to the thin film precipitation generated by adding the substrate solution. This is the way to go.
- the prepared monoclonal antibody was used as a capture antibody to be immobilized on a silicon wafer having a silicon nitride thin film layer by the 0IA method.
- an AMGC-1 monoclonal antibody capable of non-specifically reacting with Ribosomal Protein L7 / L12 proteins of various microorganisms described in Reference Examples, which was enzymatically labeled with peroxidase, was used. That is, horseradish peroxidase (Sigma grade VI) is used for enzyme labeling, and reagent S-acetylthioacetic acid N-hydroxysuccinimide is used for binding.
- the centrifugal supernatant of the Haemophilus influenzae cell extract treated with 0.5% Triton X-100 was used as the antigen.
- 1.5 ml of a Freund's adjuvant was added to about 1.2 ml of a physiological saline solution containing 100 / zg of the antigen, and the mixture was emulsified.
- four SPF Japanese White Rabbits were subcutaneously injected and immunized. Immunization was performed 5 to 6 times every two weeks, and the antibody titer was confirmed.
- the plate was washed with a washing solution (0.02% Tween20, PBS), and serially diluted normal heron serum and post-immunized rabbit herb antiserum 100 // 1 were added.
- a washing solution 0.02% Tween20, PBS
- serially diluted normal heron serum and post-immunized rabbit herb antiserum 100 // 1 were added.
- 100 ng / ml of a peroxidase-labeled anti-rabbit IgG antibody solution carry out the reaction at room temperature for 1 hour, remove the supernatant, wash with the washing solution, and then wash with the 0PD solution ( (Sigma) were added in 100 ⁇ l portions, and the reaction was carried out at room temperature for 20 minutes. After color development, the reaction was stopped by adding 100 ⁇ l of 1N sulfuric acid, and the absorbance at 492 mn was measured.
- Blood was collected from the ear artery into a glass centrifuge tube, allowed to stand at 37 ° C for 1 hour, and then allowed to stand at 4 ° C. Thereafter, the mixture was centrifuged at 3000 rpm for 5 minutes, and the supernatant was recovered.
- the obtained 4 lots of antiserum were stored at 4 ° C.
- Buffer A 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3
- Buffer B 0.1 M acetic acid, 0.5 M NaCK pH 4
- Buffer 6 ml of A was injected and left at 25 ° C. for 15 minutes.
- 6 ml of Buffer B, 6 ml of Buffer A, and 6 ml of Buffer B were flowed. Thereafter, the mixture was equilibrated with 6 ml of PBS.
- the polyclonal antibody thus purified was evaluated by the 0IA method in the same manner as in Example 6.
- the purified antibody was used as a capture antibody in the 0IA method.
- the detect antibody the AMGC-1 monoclonal antibody described in Reference Example was used as a peroxidase.
- the one labeled with an enzyme was used. Enzyme labeling is performed using horseradish peroxidase (Sigma grade VI) and binding is performed using the reagent S-acetylthioacetic acid N-hydroxysuccinimide. Analytical Biochemistry 32 (1983), 68-73 was performed according to the method described in
- a solution prepared by diluting a purified polyclonal antibody in PBS containing 0.05% sodium azide to a concentration of 10 zg / ml with 0.1 M HEPES pH 8.0 was added to the silicon wafer 50 ⁇ 1 and the mixture was added at room temperature. After reacting for 30 minutes, it was used after washing with distilled water.
- the so-called sandwich assay method in which the antigen is generally sandwiched between the capture antibody and the labeled antibody for detection, is particularly useful because of its high detection sensitivity.
- an antibody that specifically reacts with an antigenic substance derived from the target microorganism is required, and at the same time, another antibody that recognizes an antigen epitope different from the specific antibody is required.
- Antibodies that react nonspecifically with Ribosomal Protein L7 / L12 proteins derived from various microorganisms are very useful as antibodies that can constitute a sandwich assay with antibodies that specifically react with Ribosomal Protein L7 / L12 proteins It is.
- the Ribosomal Protein L7 / L12 protein has regions where the amino acid sequences are homologous in various microorganisms.
- a monoclonal antibody that cross-reacts with the Ribosomal Protein L7 / L12 proteins of various microorganisms from Neisseria gonorrhoeae is shown here. And found that non-specific anti-Ribosomal Protein L7 / L12 protein antibodies obtained from one microorganism can be used in common for various microorganisms in the San German Chiassy.
- the Ribosomal Protein L7 / L12 gene was cloned from Neisseria gonorrhoeae, large-scale expression and purification of the protein in Escherichia coli, and monoclonal antibodies against the protein were produced.
- Nei sseria gonorrhoeae I ID821 strain (sale from the University of Tokyo Institute of Medical Science, purchase) the after inoculated appropriate amount on chocolate agar, C0 2 incubator in one among at 37 ° C, C0 2 0. 5 % Conditions Incubate for 24 hours. Suspend the grown colonies in TE Buffer to a final concentration of about 5 ⁇ 10 9 CFU / ml. Transfer about 1.5 ml to a microcentrifuge tube, centrifuge at lOOOOrpm for 2 minutes, and discard the supernatant. Resuspend the pellet in 567 ju 1 of TE Buffer.
- PCR was performed using lOng of this genomic DNA. PCR used Taq polymerase (Takara Shuzo Co., Ltd., code R001A).
- the buffer attached to the enzyme is 5 AiL, and the dNTP mixture 4 / zl attached to the enzyme is similar to the Ribosomal Protein L7 / L12 DNA sequence of bacteria such as Haemophilus influenzae and the Internet.
- the sequence shown in SEQ ID NO: 15 was designed based on the Ribosomal Protein L7 / L12 DNA sequence of Nei sseria gonorrhoeae obtained from the information (University of Oklahoma, Nei sseria gonorrhoeae genomic project open genome DNA).
- Oligonucleotide E and synthetic oligonucleotide F shown in SEQ ID NO: 16 in the Sequence Listing were used as probes, and 200 pmol of each was added to give a final volume of 501.
- This mixture was subjected to 5 cycles of 95 ° C for 1 minute, 50 ° C for 2 minutes, and 72 ° C for 3 minutes using TaKaRa PCR Thermal Cycler 480, and then 95 ° C for 1 minute, 60 ° C for 2 minutes, and 72 ° C for 2 minutes. 25 cycles of 3 minutes at ° C.
- a portion of this PCR product was subjected to electrophoresis in a 1.5% agarose gel, stained with ethidium bromide (manufactured by Nippon Gene Co., Ltd.), and observed under ultraviolet light. Confirmed that. After digestion with restriction enzymes BamHI and Xhol, electrophoresis was performed in 1.5% agarose gel. After staining with ethidium bromide, a band of about 370 bp was cut out from the gel, purified with SuprecOl (Takara Shuzo), and then marketed.
- Vector pGEX-4T-1 Vector pGEX-4T-1
- the DNA-incorporated vector pGEX-4T-1 was transfected into Escherichia coli One Shot Competent Cells (Invitrogen), and L-Broth (Takara Shuzo) containing 50 ⁇ g / ml ampicillin (Sigma) was used.
- L-Broth Takara Shuzo
- the culture was shake-cultured at ° C, the cells were collected, the plasmid was separated using Wizard Miniprep (Promega) according to the attached instructions, and this plasmid was purified using the restriction enzymes BamHI / XhoI. It was confirmed that the PCR product had been incorporated by excision and the DNA of about 370 bp was cut out, and the nucleotide sequence of the incorporated DNA was determined for the confirmed clone.
- the nucleotide sequence of the inserted DNA fragment was determined using a fluorescent theta sensor manufactured by Applied Biosystems. Preparation of sequence samples PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems) was used. In a 0.5 ml microtube, add 9.51 reaction stock solution, 4. ⁇ of 0.8 pmol // l T7 promoter primer (manufactured by GIBCO BRL) and 6.5 zl of 0.16 iig / l type I DNA for sequence.
- sequence sample was dissolved in 4 zl of formamide containing 10 mM EDTA, denatured at 90 ° C for 2 minutes, cooled on ice, and subjected to the sequence.
- One of the five clones obtained had sequence homology with the probe used for PCR, and was very similar to the sequence of other microorganisms such as the Ribosomal Protein L7 / L12 gene of Haemophilus influenzae.
- the DNA sequence was found. The entire nucleotide sequence of the structural gene portion and the corresponding amino acid sequence were as shown in SEQ ID NOs: 21 and 22 in the Sequence Listing.
- This gene fragment clearly encodes the gene for the Ribosomal Protein L7 / L12 protein of Neisseria gonorrhoeae.
- the GST fusion Ribosomal Protein L7 / L12 of Neisseria gonorrhoeae purified by the same method as described in Example 2 using the constructed Rissomal Protein L7 / L12 GST fusion protein expression vector of Neisseria gonorrhoeae L12 protein was obtained.
- a hybridoma DOGC strain AMGC1 which was produced as a monoclonal antibody against the Ribosomal Protein L7 / L12 protein of Neisseria gonorrhoeae was obtained by the method described in Example 3 and the
- monoclonal antibodies were produced and recovered according to a standard method. Specifically, cells subcultured using RPMI1640 medium (containing 10% FCS) 2 X 10 5 cells in 25 cm 2 culture flasks / ml, 3. to 3 X 10 5 and 5 X 10 approximately 5 cells / ml of the diluted whole picture in serum-free medium was 5 ml. Grow at 3 ° C for 2 to 5 days at 37 ° C and select the flask with the least number of original cells among the flasks in which cell growth was observed.Finally, dilute 2 x 10 5 cells / ml.
- the same operation was repeated until the cells grew to 2 ⁇ 10 6 cells / ml in 3 to 4 days, and the cells were adapted to a serum-free medium.
- cloning was performed in a 96-well plate for bacterial culture, and cells that grew rapidly and had high antibody titers were selected.
- the selected cells grown in a 24-well plate were diluted with a serum-free medium to a total volume of 10 ml in a 25 cm 2 culture flask at a concentration of about 2 ⁇ 10 5 cells / ml.
- the culture supernatant was stored at 4 ° C after addition of 0.1% sodium azide. After diluting 100 ml of the obtained antibody-containing solution 5 times with PBS, absorb it onto a Protein A column (5 ml bed volume, manufactured by Pharmacia), wash with 3 bed volumes with PBS, and elute with pH 3.0 citrate buffer. Then, the antibody fraction was recovered to obtain a monoclonal antibody produced by each hybridoma. Evaluation was performed by ELISA using the monoclonal antibody derived from the hybridoma.
- Antibodies were evaluated using a 96-well plate sensitized with Ribosomal Protein L7 / L12 proteins derived from various microorganisms as antigens. After reacting the prepared monoclonal antibodies, the horseradish pellicle of anti-mouse IgG was used as a secondary antibody. The reaction was carried out with an oxidase label (MB330, Code330) and finally detected with an enzyme reaction coloring reagent.
- MB330, Code330 an oxidase label
- the AMGC1 antibody obtained here is used in combination with an anti-Ribosomal Protein L7 / L12 protein antibody specific for each microorganism in the detection of microorganisms by the so-called sandwich assay method such as the detection of microorganisms by Optical Immunoassay ELISA. Very useful as an antibody.
- various microorganisms can be tested against intracellular molecules having the same function.
- detecting microorganisms using the body it is possible to specifically detect microorganisms and accurately detect microorganisms of all serotypes within the same species.
- ⁇ body can be used to detect Haemophi lus influenzae, Streptococcus pneumoniae and Neisseria gonorrhoeae ft times.
- a reagent kit for detecting microorganisms comprising such an antibody as a component, the detection of microorganisms can be performed more generally and accurately.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69921329T DE69921329T2 (de) | 1998-07-31 | 1999-07-30 | Anti-l7/l12-antikörper zum nachweis von bakterien |
CA2338989A CA2338989C (en) | 1998-07-31 | 1999-07-30 | Antibodies for detecting microorganisms |
AU49317/99A AU767270B2 (en) | 1998-07-31 | 1999-07-30 | Antibody for detecting microorganism |
AT99933198T ATE280183T1 (de) | 1998-07-31 | 1999-07-30 | Anti-l7/l12-antikörper zum nachweis von bakterien |
NZ509577A NZ509577A (en) | 1998-07-31 | 1999-07-30 | Antibodies for ribosmal proteins specific to only one microorganism genus or species |
EP99933198A EP1104772B1 (en) | 1998-07-31 | 1999-07-30 | Anti-l7/l12 antibody for detecting bacteria |
JP2000562399A JP5219057B2 (ja) | 1998-07-31 | 1999-07-30 | 微生物検出用抗体 |
US12/424,370 US20090269789A1 (en) | 1998-07-31 | 2009-04-15 | Antibodies for detecting microorganisms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/230204 | 1998-07-31 | ||
JP23020498 | 1998-07-31 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/000625 Continuation-In-Part WO2001057089A1 (en) | 1998-07-31 | 2001-01-31 | Antibody for detecting chlamydia pneumoniae |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09744910 A-371-Of-International | 2001-05-17 | ||
US10/386,050 Continuation-In-Part US20040014943A1 (en) | 1998-07-31 | 2003-03-12 | Antibodies for detecting microorganisms |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000006603A1 true WO2000006603A1 (fr) | 2000-02-10 |
Family
ID=16904216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/004122 WO2000006603A1 (fr) | 1998-07-31 | 1999-07-30 | Anticorps pour la detection de micro-organismes |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1104772B1 (ja) |
JP (2) | JP5219057B2 (ja) |
KR (1) | KR100771275B1 (ja) |
CN (1) | CN1317014A (ja) |
AT (1) | ATE280183T1 (ja) |
AU (1) | AU767270B2 (ja) |
CA (1) | CA2338989C (ja) |
DE (1) | DE69921329T2 (ja) |
ID (1) | ID27972A (ja) |
NZ (1) | NZ509577A (ja) |
TW (1) | TWI231299B (ja) |
WO (1) | WO2000006603A1 (ja) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057089A1 (en) * | 2000-01-31 | 2001-08-09 | Asahi Kasei Kabushiki Kaisha | Antibody for detecting chlamydia pneumoniae |
JP2004201605A (ja) * | 2002-12-26 | 2004-07-22 | Asahi Kasei Corp | レジオネラ属菌リボソームl7/l12タンパク質をコードするdna |
JP2010248129A (ja) * | 2009-04-16 | 2010-11-04 | Asahi Kasei Corp | レジオネラ菌検出用抗体 |
JP2012122921A (ja) * | 2010-12-10 | 2012-06-28 | Asahi Kasei Corp | 乳汁中の特定物質を検出する方法 |
WO2013186885A1 (ja) | 2012-06-13 | 2013-12-19 | 旭化成株式会社 | 乳汁中の特定物質を検出する方法 |
WO2015093545A1 (ja) | 2013-12-18 | 2015-06-25 | 旭化成株式会社 | 乳汁中の大腸菌群を検出する方法 |
WO2015093544A1 (ja) | 2013-12-18 | 2015-06-25 | 旭化成株式会社 | 乳汁中のブドウ球菌を検出する方法 |
WO2015093546A1 (ja) | 2013-12-18 | 2015-06-25 | 旭化成株式会社 | 乳汁中のストレプトコッカス属の菌を検出する方法 |
JP2017207333A (ja) * | 2016-05-17 | 2017-11-24 | 旭化成株式会社 | 細菌を検出する方法及びキット |
US10435457B2 (en) | 2015-08-06 | 2019-10-08 | President And Fellows Of Harvard College | Microbe-binding molecules and uses thereof |
US10501729B2 (en) | 2013-05-21 | 2019-12-10 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
US10513546B2 (en) | 2013-12-18 | 2019-12-24 | President And Fellows Of Harvard College | CRP capture/detection of gram positive bacteria |
US10526399B2 (en) | 2011-07-18 | 2020-01-07 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
US10538562B2 (en) | 2010-01-19 | 2020-01-21 | President And Fellows Of Harvard College | Engineered opsonin for pathogen detection and treatment |
US10551379B2 (en) | 2013-03-15 | 2020-02-04 | President And Fellows Of Harvard College | Methods and compositions for improving detection and/or capture of a target entity |
WO2020045671A1 (ja) | 2018-08-31 | 2020-03-05 | 旭化成株式会社 | 検体中の被分析物質を検出するための増感剤、及び検体中の被分析物質の検出方法 |
WO2020111272A1 (ja) * | 2018-11-30 | 2020-06-04 | 旭化成株式会社 | 細菌感染による急性副鼻腔炎の起炎菌の検出方法 |
WO2020111223A1 (ja) | 2018-11-30 | 2020-06-04 | 旭化成株式会社 | ***炎の原因菌の検出方法 |
JP2021069357A (ja) * | 2019-11-01 | 2021-05-06 | 旭化成株式会社 | 検体中の緑膿菌を検出するための抗体、並びに斯かる抗体を用いて緑膿菌を検出するための方法、試薬、及びキット |
JP2021069358A (ja) * | 2019-11-01 | 2021-05-06 | 旭化成株式会社 | 検体中の黄色ブドウ球菌を検出するための抗体、並びに斯かる抗体を用いて黄色ブドウ球菌を検出するための方法、試薬、及びキット |
JP2021087355A (ja) * | 2019-11-01 | 2021-06-10 | 旭化成株式会社 | 検体中の肺炎球菌を検出するための抗体、並びに斯かる抗体を用いて肺炎球菌を検出するための方法、試薬、及びキット |
JP2021087354A (ja) * | 2019-11-01 | 2021-06-10 | 旭化成株式会社 | 検体中のインフルエンザ菌を検出するための抗体、並びに斯かる抗体を用いてインフルエンザ菌を検出するための方法、試薬、及びキット |
JP2021156799A (ja) * | 2020-03-27 | 2021-10-07 | 旭化成株式会社 | 検体中のインフルエンザ菌と肺炎球菌の免疫学的同時検出方法、及びイムノクロマトグラフィー装置 |
JP2021164415A (ja) * | 2020-04-06 | 2021-10-14 | 旭化成株式会社 | 検体中の大腸菌を検出するための抗体、並びに斯かる抗体を用いて大腸菌を検出するための方法、試薬、及びキット |
JP2021164416A (ja) * | 2020-04-06 | 2021-10-14 | 旭化成株式会社 | 検体中のモラクセラ・カタラーリス菌を検出するための抗体、並びに斯かる抗体を用いてモラクセラ・カタラーリス菌を検出するための方法、試薬、及びキット |
WO2022154094A1 (ja) | 2021-01-15 | 2022-07-21 | 旭化成株式会社 | 飲食品検体、環境検体、又は生体検体中の細菌の有無及び/又は存在量を検出するための方法及びキット |
WO2022154096A1 (ja) | 2021-01-15 | 2022-07-21 | 旭化成株式会社 | 飲食品検体、環境検体、又は生体検体中の腸内細菌科細菌の有無及び/又は存在量を検出するための方法及びキット |
WO2022210594A1 (ja) | 2021-03-29 | 2022-10-06 | 旭化成株式会社 | 淋菌検出キット及び淋菌検出方法 |
WO2023095845A1 (ja) | 2021-11-24 | 2023-06-01 | 旭化成株式会社 | 溶菌方法、及び細菌検出方法 |
WO2023095843A1 (ja) | 2021-11-24 | 2023-06-01 | 旭化成株式会社 | イムノクロマト装置及びその製造方法、並びにそれを用いた対象細菌の検出方法 |
WO2024111665A1 (ja) | 2022-11-24 | 2024-05-30 | 旭化成株式会社 | 溶菌方法、溶菌助液、及び細菌の有無の判定方法 |
JP7521922B2 (ja) | 2020-04-06 | 2024-07-24 | 旭化成株式会社 | 検体中の淋菌を検出するための抗体、並びに斯かる抗体を用いて淋菌を検出するための方法、試薬、及びキット |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI521063B (zh) | 2015-03-10 | 2016-02-11 | 國立交通大學 | 生物感測裝置及分離生物分子的方法 |
EP3634634A4 (en) * | 2017-06-06 | 2021-03-10 | Northwestern University | TRANS-INTERFACIAL MAGNETIC SEPARATION |
KR102053749B1 (ko) | 2018-01-24 | 2020-01-22 | 강원대학교산학협력단 | 임질균 특이적 항체 및 이의 용도 |
US20210332419A1 (en) * | 2018-09-26 | 2021-10-28 | Adaptive Phage Therapeutics, Inc. | Monitoring host cell contamination of virus-based biological products |
JP7491679B2 (ja) * | 2019-11-01 | 2024-05-28 | 旭化成株式会社 | 検体中のサルモネラ菌を検出するための抗体、並びに斯かる抗体を用いてサルモネラ菌を検出するための方法、試薬、及びキット |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01500083A (ja) * | 1986-05-01 | 1989-01-19 | ワシントン リサーチ ファウンデイション | 急性呼吸疾患に関連する独特のクラミジア株の検出 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3752172T3 (de) * | 1986-11-24 | 2008-04-10 | Gen-Probe Inc., San Diego | Nukleinsäuresonden zum Nachweis und/oder zur Quantifizierung von nicht-viralen Organismen |
AU655599B2 (en) * | 1990-09-11 | 1995-01-05 | Institute For Child Health Research | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
DE4128454A1 (de) * | 1991-08-28 | 1993-03-04 | Riedel De Haen Ag | Monoklonaler antikoerper, der mit pseudomonas aeruginosa reagiert |
JPH06125784A (ja) * | 1992-01-17 | 1994-05-10 | Takeda Chem Ind Ltd | モノクローナル抗体,ハイブリドーマ,その製造法および用途 |
JPH07316194A (ja) * | 1993-02-26 | 1995-12-05 | Takeda Chem Ind Ltd | Pacapレセプター蛋白質、その製造法および用途 |
WO1996007910A1 (fr) * | 1994-09-02 | 1996-03-14 | Meiji Milk Products Company Limited | Substance pour le diagnostic de l'infection par le chlamydia |
JPH0931097A (ja) * | 1995-07-24 | 1997-02-04 | Yuka Medeiasu:Kk | クラミジア・トラコマティス抗体の測定法 |
JP3708210B2 (ja) * | 1996-04-03 | 2005-10-19 | 協和醗酵工業株式会社 | 抗線維芽細胞増殖因子−8モノクローナル抗体 |
-
1999
- 1999-07-30 EP EP99933198A patent/EP1104772B1/en not_active Expired - Lifetime
- 1999-07-30 AT AT99933198T patent/ATE280183T1/de active
- 1999-07-30 ID IDW20010470A patent/ID27972A/id unknown
- 1999-07-30 CN CN99810707A patent/CN1317014A/zh active Pending
- 1999-07-30 WO PCT/JP1999/004122 patent/WO2000006603A1/ja active IP Right Grant
- 1999-07-30 CA CA2338989A patent/CA2338989C/en not_active Expired - Lifetime
- 1999-07-30 KR KR1020017001292A patent/KR100771275B1/ko not_active IP Right Cessation
- 1999-07-30 AU AU49317/99A patent/AU767270B2/en not_active Expired
- 1999-07-30 JP JP2000562399A patent/JP5219057B2/ja not_active Expired - Lifetime
- 1999-07-30 NZ NZ509577A patent/NZ509577A/xx not_active IP Right Cessation
- 1999-07-30 DE DE69921329T patent/DE69921329T2/de not_active Expired - Lifetime
- 1999-08-31 TW TW088115075A patent/TWI231299B/zh not_active IP Right Cessation
-
2010
- 2010-06-29 JP JP2010147122A patent/JP2010268800A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01500083A (ja) * | 1986-05-01 | 1989-01-19 | ワシントン リサーチ ファウンデイション | 急性呼吸疾患に関連する独特のクラミジア株の検出 |
Non-Patent Citations (3)
Title |
---|
JAN KOLBERG ET AL: "Monoclonal Antibodies Against Streptococcus Pneumoniae Detect Epitopes on Eubacterial Ribosomal Protein L7/L12 and on Streptococcal Elongation Factor Ts", MICROBIOLOGY, vol. 143, no. 1, 1997, pages 55 - 61, XP002925389 * |
KITA E. ET AL: "Analysis of Immune Responses in Genital Tracts of Mice Immunised with Purified Ribosomal Fractions Neisseria-Gonorrhoeae", BRITISH JOURNAL OF VENEREAL DISEASES, vol. 60, no. 4, 1984, pages 219 - 225, XP000905316 * |
SERGYL LAFONT ET AL: "Induction of Murine B Cell Proliferation and Immunoglobulin Synthesis by Some Bacterial Ribosomes", MICROBIOL. IMMUNOL.,, vol. 32, no. 10, 1988, pages 1043 - 1058, XP002925390 * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057089A1 (en) * | 2000-01-31 | 2001-08-09 | Asahi Kasei Kabushiki Kaisha | Antibody for detecting chlamydia pneumoniae |
JP2004201605A (ja) * | 2002-12-26 | 2004-07-22 | Asahi Kasei Corp | レジオネラ属菌リボソームl7/l12タンパク質をコードするdna |
JP2010248129A (ja) * | 2009-04-16 | 2010-11-04 | Asahi Kasei Corp | レジオネラ菌検出用抗体 |
US11203623B2 (en) | 2010-01-19 | 2021-12-21 | President And Fellows Of Harvard College | Engineered opsonin for pathogen detection and treatment |
US11059874B2 (en) | 2010-01-19 | 2021-07-13 | President And Fellows Of Harvard College | Engineered opsonin for pathogen detection and treatment |
US11059873B2 (en) | 2010-01-19 | 2021-07-13 | President And Fellows Of Harvard College | Engineered opsonin for pathogen detection and treatment |
US10538562B2 (en) | 2010-01-19 | 2020-01-21 | President And Fellows Of Harvard College | Engineered opsonin for pathogen detection and treatment |
JP2012122921A (ja) * | 2010-12-10 | 2012-06-28 | Asahi Kasei Corp | 乳汁中の特定物質を検出する方法 |
US10865235B2 (en) | 2011-07-18 | 2020-12-15 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
US11795212B2 (en) | 2011-07-18 | 2023-10-24 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
US10526399B2 (en) | 2011-07-18 | 2020-01-07 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
WO2013186885A1 (ja) | 2012-06-13 | 2013-12-19 | 旭化成株式会社 | 乳汁中の特定物質を検出する方法 |
US10551379B2 (en) | 2013-03-15 | 2020-02-04 | President And Fellows Of Harvard College | Methods and compositions for improving detection and/or capture of a target entity |
US10501729B2 (en) | 2013-05-21 | 2019-12-10 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
US11939608B2 (en) | 2013-05-21 | 2024-03-26 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
US11312949B2 (en) | 2013-05-21 | 2022-04-26 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
WO2015093545A1 (ja) | 2013-12-18 | 2015-06-25 | 旭化成株式会社 | 乳汁中の大腸菌群を検出する方法 |
US11718651B2 (en) | 2013-12-18 | 2023-08-08 | President And Fellows Of Harvard College | CRP capture/detection of gram positive bacteria |
US10513546B2 (en) | 2013-12-18 | 2019-12-24 | President And Fellows Of Harvard College | CRP capture/detection of gram positive bacteria |
WO2015093546A1 (ja) | 2013-12-18 | 2015-06-25 | 旭化成株式会社 | 乳汁中のストレプトコッカス属の菌を検出する方法 |
WO2015093544A1 (ja) | 2013-12-18 | 2015-06-25 | 旭化成株式会社 | 乳汁中のブドウ球菌を検出する方法 |
US11034744B2 (en) | 2013-12-18 | 2021-06-15 | President And Fellows Of Harvard College | CRP capture/detection of gram positive bacteria |
US11236149B2 (en) | 2015-08-06 | 2022-02-01 | President And Fallows Of Harvard College | Microbe-binding molecules and uses thereof |
US11807677B2 (en) | 2015-08-06 | 2023-11-07 | President And Fellows Of Harvard College | Microbe-binding molecules and uses thereof |
US10435457B2 (en) | 2015-08-06 | 2019-10-08 | President And Fellows Of Harvard College | Microbe-binding molecules and uses thereof |
US10696733B2 (en) | 2015-08-06 | 2020-06-30 | President And Fellows Of Harvard College | Microbe-binding molecules and uses thereof |
JP2017207333A (ja) * | 2016-05-17 | 2017-11-24 | 旭化成株式会社 | 細菌を検出する方法及びキット |
WO2020045671A1 (ja) | 2018-08-31 | 2020-03-05 | 旭化成株式会社 | 検体中の被分析物質を検出するための増感剤、及び検体中の被分析物質の検出方法 |
WO2020111272A1 (ja) * | 2018-11-30 | 2020-06-04 | 旭化成株式会社 | 細菌感染による急性副鼻腔炎の起炎菌の検出方法 |
WO2020111223A1 (ja) | 2018-11-30 | 2020-06-04 | 旭化成株式会社 | ***炎の原因菌の検出方法 |
JPWO2020111272A1 (ja) * | 2018-11-30 | 2021-09-30 | 旭化成株式会社 | 細菌感染による急性副鼻腔炎の起炎菌の検出方法 |
JP2021069358A (ja) * | 2019-11-01 | 2021-05-06 | 旭化成株式会社 | 検体中の黄色ブドウ球菌を検出するための抗体、並びに斯かる抗体を用いて黄色ブドウ球菌を検出するための方法、試薬、及びキット |
JP2021087355A (ja) * | 2019-11-01 | 2021-06-10 | 旭化成株式会社 | 検体中の肺炎球菌を検出するための抗体、並びに斯かる抗体を用いて肺炎球菌を検出するための方法、試薬、及びキット |
JP2021069357A (ja) * | 2019-11-01 | 2021-05-06 | 旭化成株式会社 | 検体中の緑膿菌を検出するための抗体、並びに斯かる抗体を用いて緑膿菌を検出するための方法、試薬、及びキット |
WO2021085651A1 (ja) * | 2019-11-01 | 2021-05-06 | 旭化成株式会社 | 検体中の黄色ブドウ球菌を検出するための抗体、並びに斯かる抗体を用いて黄色ブドウ球菌を検出するための方法、試薬、及びキット |
JP2021087354A (ja) * | 2019-11-01 | 2021-06-10 | 旭化成株式会社 | 検体中のインフルエンザ菌を検出するための抗体、並びに斯かる抗体を用いてインフルエンザ菌を検出するための方法、試薬、及びキット |
JP2021156799A (ja) * | 2020-03-27 | 2021-10-07 | 旭化成株式会社 | 検体中のインフルエンザ菌と肺炎球菌の免疫学的同時検出方法、及びイムノクロマトグラフィー装置 |
JP2021164416A (ja) * | 2020-04-06 | 2021-10-14 | 旭化成株式会社 | 検体中のモラクセラ・カタラーリス菌を検出するための抗体、並びに斯かる抗体を用いてモラクセラ・カタラーリス菌を検出するための方法、試薬、及びキット |
JP2021164415A (ja) * | 2020-04-06 | 2021-10-14 | 旭化成株式会社 | 検体中の大腸菌を検出するための抗体、並びに斯かる抗体を用いて大腸菌を検出するための方法、試薬、及びキット |
JP7521922B2 (ja) | 2020-04-06 | 2024-07-24 | 旭化成株式会社 | 検体中の淋菌を検出するための抗体、並びに斯かる抗体を用いて淋菌を検出するための方法、試薬、及びキット |
WO2022154096A1 (ja) | 2021-01-15 | 2022-07-21 | 旭化成株式会社 | 飲食品検体、環境検体、又は生体検体中の腸内細菌科細菌の有無及び/又は存在量を検出するための方法及びキット |
WO2022154094A1 (ja) | 2021-01-15 | 2022-07-21 | 旭化成株式会社 | 飲食品検体、環境検体、又は生体検体中の細菌の有無及び/又は存在量を検出するための方法及びキット |
WO2022210594A1 (ja) | 2021-03-29 | 2022-10-06 | 旭化成株式会社 | 淋菌検出キット及び淋菌検出方法 |
KR20230148421A (ko) | 2021-03-29 | 2023-10-24 | 아사히 가세이 가부시키가이샤 | 임균 검출 키트 및 임균 검출 방법 |
WO2023095845A1 (ja) | 2021-11-24 | 2023-06-01 | 旭化成株式会社 | 溶菌方法、及び細菌検出方法 |
WO2023095843A1 (ja) | 2021-11-24 | 2023-06-01 | 旭化成株式会社 | イムノクロマト装置及びその製造方法、並びにそれを用いた対象細菌の検出方法 |
WO2024111665A1 (ja) | 2022-11-24 | 2024-05-30 | 旭化成株式会社 | 溶菌方法、溶菌助液、及び細菌の有無の判定方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2338989C (en) | 2010-07-27 |
NZ509577A (en) | 2003-01-31 |
JP2010268800A (ja) | 2010-12-02 |
AU4931799A (en) | 2000-02-21 |
AU767270B2 (en) | 2003-11-06 |
JP5219057B2 (ja) | 2013-06-26 |
ID27972A (id) | 2001-05-03 |
CA2338989A1 (en) | 2000-02-10 |
EP1104772B1 (en) | 2004-10-20 |
EP1104772A1 (en) | 2001-06-06 |
CN1317014A (zh) | 2001-10-10 |
EP1104772A4 (en) | 2002-06-05 |
KR100771275B1 (ko) | 2007-10-29 |
ATE280183T1 (de) | 2004-11-15 |
DE69921329D1 (de) | 2004-11-25 |
KR20010072121A (ko) | 2001-07-31 |
TWI231299B (en) | 2005-04-21 |
DE69921329T2 (de) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000006603A1 (fr) | Anticorps pour la detection de micro-organismes | |
US6828110B2 (en) | Assays for detection of Bacillus anthracis | |
JP2012006968A (ja) | マイコプラズマ・ニューモニア検出用抗体 | |
KR101952332B1 (ko) | 마이코플라즈마·뉴모니에 및/또는 마이코플라즈마·제니탈륨에 속하는 미생물을 검출하는 방법 | |
JP5442641B2 (ja) | 全インフルエンザ菌の測定方法 | |
US5474905A (en) | Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens | |
US7374888B2 (en) | Methods for detecting B. anthracis infection | |
US20090269789A1 (en) | Antibodies for detecting microorganisms | |
JPH06506114A (ja) | 新規な遺伝子及びIgA結合蛋白質の製造方法 | |
Shin et al. | Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes | |
JP2012017334A (ja) | クラミジア・ニューモニア検出用抗体 | |
JP2002533083A (ja) | 遺伝子およびたんぱく質、およびそれらの用途 | |
US7393647B2 (en) | Methods for detecting B. anthracis infection | |
JPH022357A (ja) | ヘモフィルス・インフルエンゼb型主外層膜蛋白質抗原の製造方法および組成物 | |
WO2020111272A1 (ja) | 細菌感染による急性副鼻腔炎の起炎菌の検出方法 | |
JP5351367B2 (ja) | クラミジア・トラコマチス検出用抗体 | |
JPH08333397A (ja) | クラミジア・ニューモニエに特異的な標識化モノクローナル抗体、クラミジア・ニューモニエ検出・測定用試薬及びその試薬並びにクラミジア・ニューモニエ感染の診断薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99810707.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2000 562399 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 509577 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2338989 Country of ref document: CA Ref document number: 2338989 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017001292 Country of ref document: KR Ref document number: 49317/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/147/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999933198 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09744910 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999933198 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017001292 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 49317/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999933198 Country of ref document: EP |